1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. MIRA Pharmaceuticals Acquires SKNY Pharmaceuticals

M&A Deal Summary

MIRA Pharmaceuticals Acquires SKNY Pharmaceuticals

On March 24, 2025, MIRA Pharmaceuticals acquired life science company SKNY Pharmaceuticals

Acquisition Highlights
  • This is MIRA Pharmaceuticals’ 1st transaction in the Life Science sector.
  • This is MIRA Pharmaceuticals’ 1st transaction in the United States.

M&A Deal Summary
Date 2025-03-24
Target SKNY Pharmaceuticals
Sector Life Science
Buyer(s) MIRA Pharmaceuticals
Deal Type Add-on Acquisition

Target

SKNY Pharmaceuticals

United States
SKNY Pharmaceuticals develops SKNY-1 a preclinical-stage oral drug candidate for weight loss and smoking cessation.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

MIRA Pharmaceuticals

Miami, Florida, United States
Category Company
Founded 2020
Sector Life Science
Revenue 7M USD (2022)
DESCRIPTION

MIRA Pharmaceuticals is a clinical-stage pharmaceutical company developing breakthrough therapeutics for neurologic and neuropsychiatric disorders. MIRA Pharmaceuticals was founded in 2020 and is based in Miami, Florida.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: United States M&A 1 of 1
Year: 2025 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal